Iron oxide nanoparticle (IONP) hyperthermia is a novel therapeutic strategy currently under consideration for the treatment of various cancer types. Systemic delivery of IONP followed by non-invasive activation via a local alternating magnetic field (AMF) results in site-specific energy deposition in the IONP-containing tumor. Targeting IONP to the tumor using an antibody or antibody fragment conjugated to the surface may enhance the intratumoral deposition of IONP and is currently being pursued by many nanoparticle researchers. This strategy, however, is subject to a variety of restrictions in the in vivo environment, where other aspects of IONP design will strongly influence the biodistribution. In these studies, various targeted IONP are compared to non-targeted controls. IONP were injected into BT-474 tumor-bearing NSG mice and tissues harvested 24hrs post-injection. Results indicate no significant difference between the various targeted IONP and the non-targeted controls, suggesting the IONP were prohibitively-sized to incur tumor penetration. Additional strategies are currently being pursued in conjuncture with targeted particles to increase the intratumoral deposition.
INTRODUCTION
While direct injection of starch-coated IONP into tumor tissues has shown clinical success, reasonable doses of intravenously-delivered IONP have yet to achieve intratumoral concentrations producing the same levels of heating. The development of IONP as an MRI contrast for applications in liver cancer has resulted in clinically-accepted IONP designs (crystal core with a dextran or starch-based coating) heavily favoring sequestration by macrophages in the reticuloendothelial system (RES) (1, 2, 3) . Using this IONP design as a basis for treating other cancer types, such as breast, has resulted in minimal IONP deposition in the tumor tissue and subsequently the inability to elevate tumor temperatures with hysteretic heating.
In general, tumor tissue is known to have abnormal vessel and lymphatic networks with high variability in extracellular matrix (ECM) density (4) . While the EPR effect may favor some nanoparticle designs in this situation, not all particle designs will benefit. In order to penetrate solid tumor tissue, IONP must first maintain a serum half-life long enough to diffuse into the tumor. IONP must also be small or flexible enough, notwithstanding opsonized proteins, to diffuse through tumor vasculature as well as through ECM (5) . Various sizes, shapes and functionally-derived variants of IONP exist that may help to mitigate the low concentration problem, notably antibody-targeted and PEG-ylated IONP (6, 7, 8, 9, 10) . PEG-ylation can increase serum half life of a therapeutic by evading protein opsonization and macrophage detection (11) .
Antibody targeting may allow nanoparticles to interact with specific epitopes characteristic to the tumor environment, resulting in less diffusion out of the tumor or even the activation of targeted pathways such as internalization (12) . However, a comprehensive picture of how these variables affect starch-base coated IONP biodistribution in multiple in vitro and solid mouse tumor models is not available, though literature summaries have been attempted (13) . The most comprehensive set of studies available, from Chouly et al. at Laboratoire de Biophysique in France, tests variants of superparamagnetic dextran-coated IONP with different sizes (33-90.6 nm) and surface charges (-30 -+20mV) as well as a copolymer coating modification, however do not include tumor tissue in their mouse model (14) .
The following study attempted to assess the ability of tumor targeting and PEG-ylation, separately, to increase tumor deposition of IONP following intravenous injection. An additional smaller IONP group was also tested in one mouse to explore the difference between base particle sizes.
METHODOLOGY

Mice used for study
All mice are cared for according to approved IACUC animal protocol. Female mice of the strain NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ were obtained from The Jackson Laboratory (Bar Harbor, Maine 04609 USA) or from an in-house stock propagated from breeders originally from The Jackson Laboratory. At 8-11 weeks old, mice were implanted in mammary fat pad 10 with 5 million cells in 100µl of a three part mixture of rat tail collagen I (BD Biosciences), Matrigel TM basement membrane matrix (BD Biosciences) and serum-free DMEM-F12 50/50 using a 1ml syringe and a 30G needle. Mice were monitored every three days until the tumor reaches 50mm3, upon which mice were measured once every two days. Mice were put on study once the tumor volume reaches between 100-200mm 3 as measured by calipers and calculated using an ellipsoid approximation.
Particles used for the studies
All nanoparticles used for these studies were purchased from Micromod Partikeltechnologie GmbH (18119 Rostock-Warnemuende, GERMANY) or BioPal (80 Webster Street, Worcester, MA). 20nm (BioPal, aminodextrancoated) and 50nm SPIO (Micromod Partikeltechnologie GmbH, dextran-coated) were obtained and characterized using ferrozine assay, ICP-MS and the Malvern Zetasizer. Micromod IONP were additionally available with PEG-200 functionalization. Stock iron concentrations vary from batch to batch and were validated in house before utilizing a given batch. Batches were stored at 4˚C and used within the reported shelf life. Additional modified particles, specifically protein-targeted (TNP) and maleimide-amine-functionalized (MSPIO) associated control, were synthesized by Warren Kett.
IONP administration
Once a mouse reaches treatment size, IONP dose was calculated using mouse body mass (g). All other iron concentrations were normalized to the lowest concentration to ensure equal volume scaling. IONP stocks were made isotonic with the addition of salts (PBS, NaCl) prior to in vivo use. A 1ml syringe with 30g needle was loaded with the full injection dose and half the volume marked off. Mice were anesthetized using isoflurane and secured on a heated, vented surface for injection. Half the IONP dose was then injected intravenously into the tail vein; the mouse was then allowed to wake up and return to her cage. Two hours following the first injection, the syringe was drawn back to recoup any void volume in the needle and the needle was replaced with a fresh tip. The mouse was re-anesthetized and injected with the second half of the IONP dose. Two hours was chosen in order to allow the large injection volume and subsequent spike in blood pressure to normalize, as after one hour injections were noted to be challenging and incur excessive bleeding at the injection site after needle withdrawal. Timepoints are read after the second injection. An equal volume PBS control injection group was completed to evaluate background tissue iron concentrations.
Tissue harvesting
At a given timepoint following the second injection, mice were anesthetized using an overdose of isoflurane. At least 10 seconds after respiration is no longer observed, the mouse was checked for pain stimulus response by pinching the leg before collecting 100-400µl of blood via intracardial blood draw. The tumor was then removed and placed on a pre-weighed weigh boat for massing. Remaining organs of interest, including heart, lungs, liver, spleen and kidneys, were removed and placed in a large weigh boat containing PBS to prevent tissue drying and blood clotting on the surface. Organs are removed from the PBS bath, blot-dried and massed. After weighing each whole organ, a scalpel was used to reserve part of the tissue for histology, with the piece reserved being consistently from the same region of each organ type. The histology sample was placed in a glass vial containing an excess of 10% formalin; the remaining tissue is placed in a pre-weighted 15ml conical tube (Sarstedt) and post-weighed to determine tissue mass. Fixed tissues are allowed to fix for at least 24 hours at room temperature before preparing cassettes and submitting to the Pathology Translation Research Core at Dartmouth.
Inductively Coupled Plasma Mass Spectrometry (ICP-MS) digestion protocol
The following digestion procedure occurs in a fume hood due to ammonia production. A 1:3 volumetric mixture of stock concentration trace metal grades HCl to nitric acid (Fisher Scientific) was prepared in a 50ml conical tube. The acid mixture was immediately added to the post-weighed conical tubes containing harvested tissues. A DORM-3 standard, tumor, spleen, heart and lung tissues received at least 2ml of the acid mixture while blood and kidney tissues received at least 5ml and livers receive at least 7ml. The tissues were allowed to digest at room temperature, caps vented, for at least one hour before being placed on a heat block and incubated at 60˚C for at least two hours. Vials were sealed and inverted at least twice during the heating process. Following heating, samples were allowed to cool a minimum of overnight before caps were sealed and all vials weighed and numbered. Sample data was logged in a spreadsheet and samples are submitted to the Dartmouth Trace Elements core for iron content analysis. Table 1 . IONP size (hydrodynamic diameter), polydispersity index (PDI) and zeta potential (mV) as determined using a Malvern zetasizer instrument. Samples were diluted to 1 mg Fe/ml in Millipore-filtered H 2 O with 10mM NaCl. Data for 20nm non-targeted IONP is presented as a reference. Targeted 20nm IONP were functionalized using a comparable process to 50nm IONP. Table 1 shows a summary of size and surface charge characteristics for the various IONP used. All IONP displayed near-neutral zeta potentials, however varied significantly in size depending on functionalization. The non-functionalized plain 50nm IONP had an average size of ~78nm in diameter. Adding amination and maleimide functionalization resulted in an increase in average size to 88-89 nm in diameter. Attaching the targeting moiety further increased the average size to ~95nm, as expected from the 2-3nm estimated length of the targeting protein. The PEG-ylation process, which includes base functionalization of the plain IONP variant before attachment of PEG-200, increased the average size to ~103nm, making this the largest variant tested of the set.
RESULTS
As is evident from Figure 7 , though all particle types tested displayed tumor iron values above background, only the Plain and PEG200-ylated variants were statistically different from the other IONP types (P ≤ 0.035), though not from one another. The promising single point data from the 20nm targeted particle showed high intratumoral iron even with more than 30% less injected dose. 20nm targeted IONPs may also demonstrate less liver accumulation at the 24 hour timepoint, though additional mice are required to verify either of these observations. Liver concentrations of all other particle groups are not statistically significantly different with the exception of the PEG200-ylated variant, which is different from all other groups (P ≤ 0.035), and Plain from MSPIO (P ≤ 0.03), with all others being above P = 0.05. That the PEG-ylated variant shows slightly lower liver iron concentrations than all other groups may be expected from PEG's effect on circulation, and 24 hour blood iron concentrations for the PEG group are statistically different from background (P ≤ 0.035). moieties by serum proteins, they lose the opportunity to interact with intratumoral targets. Smaller IONP and PEGylation may both enhance intratumoral IONP deposition and allow for increased exposure of IONP targeting moieties to the appropriate tumor cell surface antigens. Additional work is necessary with PEG-ylated targeted 50nm and 20nm IONP and all associated controls to see whether these variables can favorably affect targeted IONP tumor uptake. Future work includes the completion of 50nm PEG-ylated and targeted as well as 20nm targeted, PEG-ylated and both targeted and PEG-ylated IONP in order to address this hypothesis.
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